In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy: An Exploratory Study
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 19 of the 27 sources its claims cite were checked for support.
Abstract
Leakage of gadolinium-based contrast agent through the BBB can be measured in vivo in CAA from the leptomeningeal vessels, and findings point to likely leakage from cortical small vessels as well.
Overview
CoChat Summary
## TL;DR
This exploratory prospective MRI study found that gadolinium-based BBB leakage can be measured in vivo in patients with probable CAA without prior lobar ICH. Sulcal CSF enhancement was seen only in CAA (5/14, 36%) and was associated with higher cSS volume, while cortical PS was numerically higher in CAA than controls but not statistically significant.
## Key findings
- In the primary sample, 14 patients with CAA and 7 non-CAA controls with subjective cognitive complaints or MCI were studied; CAA patients had mean age 67.7 ± 9.0 years and controls 70.1 ± 6.5 years.
- Focal CSF enhancements were similarly common in CAA and controls: 7/14 (50%) vs 4/7 (57%), p = 0.98; sulcal CSF enhancements were only seen in CAA: 5/14 (36%) vs 0/7 (0%).
- In patients with CAA, focal and sulcal CSF enhancement counts were associated with higher cSS volume (focal: B = 2.61, p = 0.003; sulcal: B = 1.02, p = 0.02), but not with CMBs.
- Cortical PS was numerically higher in CAA than controls (5.08 ± 4.02 × 10−4 min−1 vs 1.29 ± 4.08 × 10−4 min−1, p = 0.07; Cohen d = 0.9), but PS was not associated with CMB count or cSS volume (p > 0.67).
## Methods
- Prospective observational exploratory substudy at Massachusetts General Hospital using participants from a memory-clinic cohort; included 14 patients with probable CAA and 7 non-CAA controls, all without prior intracerebral hemorrhage, scanned between August 2021 and September 2023.
- MRI protocol at 3T included pre/postcontrast FLAIR for CSF enhancement and 16-minute dynamic contrast-enhanced MRI after IV Dotarem for quantitative PS; optional follow-up FLAIR scans were done at 3, 6, and 24 hours in a subset (8 CAA, 2 controls).
- Group differences and associations were tested with age-corrected logistic regression, ANCOVA, t tests, and regression models; PS was estimated with the Patlak model.
## Limitations
- The paper states the main limitation was the small sample size, with low power for PS: 47% power for cortical PS group differences, and 19 participants per group would have been needed for 80% power.
- The authors note the study is exploratory and could not determine whether BBB leakage predicts disease progression or is an early marker of CAA.
- Evident from the text: the control group was not a healthy control group but participants with subjective cognitive complaints or MCI, which the authors say may underestimate between-group differences.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
13 Valid · 1 Not valid · 5 Not checked · 37 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“With postcontrast FLAIR imaging, leakage of gadolinium from the leptomeningeal vessels is visible as hyperintense signal within the CSF because of T1-relaxation time shortening by the extravasated contrast agent.11,13,14”
§ In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy > Introduction
What the sources say
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
The Introduction background states that gadolinium leakage into CSF causes T1-relaxation shortening and hyperintense signal on post-contrast FLAIR images. It describes the leakage as arising from presumed blood–brain or blood–CSF barrier disruption, but does not establish that the gadolinium specifically leaks from leptomeningeal vessels. (LLM, conf=0.83)
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
The Abstract (p.1) and Discussion of Freeze et al. 2019 support the descriptive core of the claim: pcFLAIR 'can be applied to visualize leakage of contrast material through the blood-brain barrier (BBB) into the CSF,' suppression of high-gadolinium blood signal 'makes it easier to discern leakage from leptomeningeal vessels,' and the Abstract/Summary states 'Pericortical enhancement on postcontrast FLAIR images is a marker for subtle leptomeningeal blood-brain barrier leakage,' with the Discussion and Image Analysis sections describing counted 'hyperintense foci' of CSF enhancement from contrast-agent leakage. However, our copy nowhere states the physical mechanism the sentence attributes — that the hyperintensity arises from T1-relaxation-time shortening by the extravasated agent; the paper's own mechanistic explanation (Discussion, In Vitro Experiment) concerns T2-weighting, tissue-signal suppression and proper nulling of pure CSF, and it only presupposes T1 effects implicitly by comparing sensitivity with pcT1WI. Searches for 'T1 shortening', 'relaxivity/longitudinal relaxation' returned no such statement. (LLM, conf=0.70)
- Partly supportedcites [14] sourceExperimental — accuracy not yet measured
The Discussion (para. on mechanisms of CNS enhancement) does state that 'In the leptomeningeal region, contrast leakage from vessels into the CSF is another process underlying enhancement,' with increased meningeal vessel permeability after blood-brain/blood-CSF barrier breakdown, and that this CSF/interstitial component is what postcontrast 3D T2-FLAIR depicts — so the leakage-into-CSF half of the claim is supported. However, our copy nowhere attributes the resulting CSF hyperintensity to T1-relaxation shortening by the extravasated agent; the only mention of T1 shortening is a report of another group's phantom work ('Mathews et al demonstrated that at higher Gd concentrations, 2D T2-FLAIR imaging is less sensitive to T1 shortening effects,' Discussion), and the paper's own in vitro findings are framed as sensitivity to low vs high Gd concentrations and flow-related signal loss. The mechanistic 'because of T1 shortening' portion attributed here is therefore not stated by this source (and the leakage process itself is credited to refs 18-20: Mamourian et al 2000, Bozzao et al 2003, Hirai et al 2005). (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In previous research, Alzheimer disease and cerebral small vessel disease have also been related to BBB leakage,12,33 which means that the differences observed in this study are likely to reflect changes specific to CAA, rather than the general features of cognitive impairment.”
§ In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy > Discussion
What the sources say
- Supportedcites [12] source
The Introduction (page unavailable) links increased BBB leakage with features of cerebral small vessel disease, and the DCE-MRI studies table (page unavailable) reports leakage findings in Alzheimer disease. The citation supports that background premise; the statement that this study’s differences are CAA-specific is the citing authors’ inference, not a conclusion attributed to this review. (LLM, conf=0.86)
- Supportedcites [33] source
The Introduction describes BBB leakage as a common observation in Alzheimer’s disease. The Cerebral Microbleeds section reports an association between leakage rates and white matter hyperintensities, a feature of cerebral small vessel disease, while noting that other forms need further study. The conclusion that this study’s differences are CAA-specific is the citing authors’ inference, not a finding attributed to this source. (LLM, conf=0.86)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Early blood-brain barrier (BBB) leakage may play a role in this.4,5”
§ In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy > Introduction
What the sources say
- Partly supportedcites [4] sourceExperimental — accuracy not yet measured
The ‘Altered vascular reactivity’ section (page unavailable) says amyloid deposition may cause blood-brain barrier disruption, and the pathophysiology section describes barrier breakdown as a possible contributor to injury. The copy does not establish that BBB leakage occurs early or precedes haemorrhage in CAA. (LLM, conf=0.79)
- Partly supportedcites [5] sourceExperimental — accuracy not yet measured
The Discussion (page not provided) links Aβ-driven loss of barrier integrity in CAA to both BBB leakage and cortical cerebral hemorrhage, supporting a possible mechanistic connection. It does not establish that leakage occurs early or precedes hemorrhage; the clinical observations report leakage and hemorrhage without demonstrating their sequence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In postmortem brain tissue of individuals with CAA, circulating plasma proteins fibrin(ogen) and immunoglobin G (IgG) have been observed in the walls of blood vessels without hemorrhage,7,8 indicative of a leaky BBB.”
§ In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy > Introduction
What the sources say
- Supportedcites [7] source
The Methods (Microscopic analyses; page not provided) say that vessels were counted as positive only when fibrin or IgG staining was evident within the vessel wall, and that microbleeds, if present, were excluded from the regions analyzed. The Results report fibrin- and IgG-positive vessels in postmortem CAA tissue; the paper treats these proteins’ extravasation as markers of BBB leakage. (LLM, conf=0.94)
- Partly supportedcites [8] sourceExperimental — accuracy not yet measured
The Results (Immunohistochemical analysis; page unavailable) report increased fibrinogen staining in white matter from autopsy brains of AD patients with capillary CAA, and the Discussion interprets this as evidence of BBB leakage. The paper does not report IgG in vessel walls or establish that the vessels showing protein deposition were free of hemorrhage; its fibrinogen finding also did not extend to CAA type 2 or gray matter. (LLM, conf=0.88)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In vivo, BBB leakage can be measured with contrast-enhanced MRI.11,12”
§ In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy > Introduction
What the sources say
- Supportedcites [11] source
The Introduction background explicitly states that BBB disruption can be assessed in living individuals by detecting gadolinium-based contrast-agent leakage with contrast-enhanced MRI. This directly supports the in vivo measurement claim. (LLM, conf=0.95)
- Supportedcites [12] source
The Introduction states that dynamic contrast-enhanced MRI is used to assess blood–brain barrier failure and can yield quantitative estimates of leakage rate. This directly supports the claim that BBB leakage can be measured in vivo with contrast-enhanced MRI. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
22 more claims · 3 with their cited sources checked
Create a free account to see all 56 claims and to verify the 3 references still open.
- It may state two separate claims as one. 19
- Probably not a substantial claim. 15
- Borderline: one of the tests for a substantial claim is unclear. 2
Citations
Cites
Jenkinson, M., Bannister, P., Brady, M., & Smith, S. (2002) · NeuroImage · doi:10.1006/nimg.2002.1132 · Cited by 11,888
A global optimisation method for robust affine registration of brain images
Jenkinson, M., & Smith, S. (2001) · Medical Image Analysis · doi:10.1016/s1361-8415(01)00036-6 · Cited by 6,872
Establishment and Dysfunction of the Blood-Brain Barrier
Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015) · Cell · doi:10.1016/j.cell.2015.10.067 · Cited by 1,670
Neuroimaging standards for research into small vessel disease—advances since 2013
Duering, M., Biessels, G. J., Brodtmann, A., Chen, C., Cordonnier, C., de Leeuw, F.-E., Debette, S., Frayne, R., Jouvent, E., Rost, N. S., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00131-x · Cited by 1,144 · cited 1×
“17 WMH segmentation was performed with Samseg from FreeSurfer 20 based on the T1-weighted and precontrast FLAIR scans.”
Self-citationPrevalence of superficial siderosis in patients with cerebral amyloid angiopathy
Linn, J., Halpin, A., Demaerel, P., Ruhland, J., Giese, A. D., Dichgans, M., van Buchem, M. A., Bruckmann, H., & Greenberg, S. M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dad605 · Cited by 914
Charidimou, A., Boulouis, G., Frosch, M. P., Baron, J.-C., Pasi, M., Albucher, J. F., Banerjee, G., Barbato, C., Bonneville, F., Brandner, S., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00208-3 · Cited by 723
Self-citationSynthSeg: Segmentation of brain MRI scans of any contrast and resolution without retraining
Billot, B., Greve, D. N., Puonti, O., Thielscher, A., Van Leemput, K., Fischl, B., Dalca, A. V., & Iglesias, J. E. (2023) · Medical Image Analysis · doi:10.1016/j.media.2023.102789 · Cited by 641
Emerging concepts in sporadic cerebral amyloid angiopathy
Charidimou, A., Boulouis, G., Gurol, M. E., Ayata, C., Bacskai, B. J., Frosch, M. P., Viswanathan, A., & Greenberg, S. M. (2017) · Brain · doi:10.1093/brain/awx047 · Cited by 555
Self-citationDiagnosis of Cerebral Amyloid Angiopathy: Sensitivity and Specificity of Cortical Biopsy
Greenberg, S. M., & Vonsattel, J.-P. G. (1997) · Stroke · doi:10.1161/01.str.28.7.1418 · Cited by 312
Enlarged Perivascular Spaces and Cerebral Small Vessel Disease
Potter, G. M., Doubal, F. N., Jackson, C. A., Chappell, F. M., Sudlow, C. L., Dennis, M. S., & Wardlaw, J. M. (2015) · International Journal of Stroke · doi:10.1111/ijs.12054 · Cited by 296
Research works printed but not linked: 1
- DOTAREM (Gadoterate Meglumine) Injection for Intravenous Use Initial U.S. Approval. FDA; 2013.
Cited by
Imaging and fluid biomarkers for prognostic stratification in cerebral amyloid angiopathy
Wang, D., Lv, S., Wei, Y., & Zhao, X. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13626-2 · Cited by 4
“…in vivo assessment of cerebral perfusion, blood–brain barrier integrity, and vascular reactivity, and have been increasingly applied to probe microvascular dysfunction in amyloid-related and CAA-spec-trum small vessel disease, capturing aspects not reflected by static lesion burden alone [33–35].”
Drug-Induced Amyloid-Related Imaging Abnormalities: A Neurovascular Perspective on Risk Assessment
Zedde, M., Losa, M., Donniaquio, A., Gandoglia, I., Sette, M. D., Roccatagliata, L., Piazza, F., Pardini, M., & Pascarella, R. (2026) · Pharmaceuticals · doi:10.3390/ph19040579 · Cited by 4
Losa, M., Zotin, M. C. Z., van Harten, T. W., van den Brink, H., Carr, R., Roccatagliata, L., Pardini, M., Greenberg, S. M., Viswanathan, A., van Veluw, S. J., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000218274 · Cited by 2
Self-citationMeningovascular Inflammation in Cerebral Amyloid Angiopathy‐Related Cortical Superficial Siderosis
Arndt, P., Khadhraoui, E., Müller, S. J., Neumann, K., Mattern, H., Meuth, S. G., Perosa, V., Charidimou, A., & Schreiber, S. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70315 · Cited by 2
Blood-Brain Barrier Leakage: A New Imaging Biomarker of Cerebral Amyloid Angiopathy?
Baron, J. (2025) · Neurology · doi:10.1212/wnl.0000000000214422
Metadata
- Authors
- van den Brink, H., Kozberg, M. G., Makkinejad, N., Kirsch, J. E., Thrippleton, M. J., van Harten, T. W., Voigt, S., Freeze, W. M., Van Osch, M. J. P., Viswanathan, A., & van Veluw, S. J.
- Affiliations
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston;
- Harvard University (US)
- Massachusetts General Hospital (US)
- University of Edinburgh (GB)
- Leiden University Medical Center (NL)
- Department of Radiology, Leiden University Medical Center, the Netherlands;
- ORCID
- Venue
- Neurology
- Published
- 2025-11-25
- Volume
- 105
- Issue
- 10
- Pages
- e214336-e214336
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC12590493
- OpenAlex
- W4415937459
- Cited by
- 11
- References
- 36
- Citations by year
- 2026: 10 · 2025: 1
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Neurology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Edinburgh Research Explorer (University of Edinburgh) (acceptedVersion, cc-by)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- Leiden Repository (Leiden University) (submittedVersion)
- Funders
- Foundation for Cardiovascular Research
- Fondation Leducq (23CVD03)
- Universiteit Leiden
- Universiteit Maastricht
- Maastricht Universitair Medisch Centrum
- Leids Universitair Medisch Centrum
- Alzheimer Nederland
- National Institutes of Health
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
- National Institute on Aging (R21AG070363)
- National Institute of Neurological Disorders and Stroke (R01NS104130)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Clinical Neurology › Cerebrovascular and genetic disorders
- Keywords
- cerebral amyloid angiopathy, blood-brain barrier disruption, gadolinium-based contrast agents, Dotarem, leptomeningeal vessels, superficial siderosis, cerebral microbleeds, permeability-surface area product, dynamic contrast-enhanced MRI, predictive biomarkers
- MeSH terms
- Aged, Aged, 80 and over, Blood-Brain Barrier, Brain, Cerebral Hemorrhage, Contrast Media, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Organometallic Compounds, Prospective Studies, Cerebral Amyloid Angiopathy, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy: An Exploratory Study. https://app.cochat.ai/papers/10.1212/wnl.0000000000214336
- The paper
- van den Brink, H., Kozberg, M. G., Makkinejad, N., Kirsch, J. E., Thrippleton, M. J., van Harten, T. W., Voigt, S., Freeze, W. M., Van Osch, M. J. P., Viswanathan, A., & van Veluw, S. J. (2025). In Vivo Imaging of Blood-Brain Barrier Leakage Using a Contrast Agent in Patients With Cerebral Amyloid Angiopathy: An Exploratory Study. Neurology. https://doi.org/10.1212/wnl.0000000000214336
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.